Transcriptomic analyses of human brains with Alzheimer's disease identified dysregulated epilepsy-causing genes

Abdallah M. Eteleeb[1,2¶], Suélen Santos Alves[3¶], Stephanie Buss[5,6], Mouhsin Shafi[5,6], Daniel Press[5,6], Norberto Garcia-Cairasco[3,4], Bruno A. Benitez[5,6¶*]

[1]Department of Psychiatry, Washington University, Saint Louis, St. Louis, Missouri, United States of America.

[2]The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University, St. Louis, Missouri, United States of America

[3]Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil.

[4]Department of Physiology, Ribeirão Preto Medical School - University of São Paulo (FMRP-USP), Brazil.

[5]Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

[6]Harvard Medical School, Boston, Massachusetts, United States of America

* Corresponding author: e-mail: bbenitez@bidmc.harvard.edu

[¶] Equally contributing author

Abstract

Background & Objective

Alzheimer's Disease (AD) patients at multiple stages of disease progression have a high prevalence of seizures. However, whether AD and epilepsy share pathophysiological changes remains poorly defined. In this study, we leveraged high-throughput transcriptomic data from sporadic AD cases at different stages of cognitive impairment across multiple independent cohorts and brain regions to examine the role of epilepsy-causing genes.

Methods

Epilepsy-causing genes were manually curated, and their expression levels were analyzed across bulk transcriptomic data from three AD cohorts and three brain regions. RNA-seq data from sporadic AD and control cases from the Knight ADRC, MSBB, and ROSMAP cohorts were processed and analyzed under the same analytical pipeline. An integrative clustering approach employing machine learning and multi-omics data was employed to identify molecularly defined profiles with different cognitive scores.

Results

We found several epilepsy-associated genes/pathways significantly dysregulated in a group of AD patients with more severe cognitive impairment. We observed 15 genes consistently downregulated across the three cohorts, including sodium and potassium channels, suggesting that these genes play fundamental roles in cognitive function or AD progression. Notably, we found 25 of these genes dysregulated in earlier stages of AD and become worse with AD progression.

Conclusion

Our findings showed that epilepsy-causing genes showed changes in the early and late stages of AD progression, suggesting that they might be playing a role in AD progression. We can not establish directionality or cause-effect with our findings. However, changes in the epilepsy-causing genes might underlie the presence of

seizures in AD patients, which might be present before or concurrently with the initial stages of AD.

Introduction

Evidence from studies involving rodents and humans across various research methods strongly supports the idea that network dysconnectivity and hyperexcitability are important intrinsic features of Alzheimer's disease (AD) [1]. Seizures and epileptiform activity are classic manifestations of network hyperexcitability [2]. AD is associated with an increased risk of seizures, with up to 15–20% of patients affected. Seizures are associated not only with an earlier onset of cognitive decline but also with more rapid disease progression [2]. Specific features of epileptiform discharges are associated with clinical seizures in AD. Epileptiform activity and chronic hyperexcitability promote amyloid-β (Aβ) plaque deposition and tau hyperphosphorylation [3].

A recent meta-analysis identified a 1.8-fold increased risk of AD in people with epilepsy, while patients with AD are at a 3.1-fold higher risk of epilepsy [4]. Recent studies have shown an important bidirectional connection between epilepsy and AD [5–9] and highlighted that cognitive impairment frequently coexists with epilepsy and appears to be associated with multiple phenotype variables including age, gender, educational attainment, and the dosage of antiseizure medications [10]. The rate of dementia incidence among epilepsy patients has been shown to increase, particularly among the elderly [5,11]. This relationship has been further reported to be associated with worse clinical outcomes and shorter lifespans [12,13]. Furthermore, increasing evidence suggests that people who develop epilepsy after the age of 40, without a known cause, are more likely to develop AD compared to those who do not have epilepsy [5]. The association between AD and epilepsy, particularly mesial temporal lobe epilepsy, has led researchers to identify a potential new subtype of AD characterized by more substantial neuronal loss and a rapid decline in cognitive and clinical functions [8]. A causal association between AD and generalized epilepsy was observed, and this association was robust to sensitivity analyses. It was further validated by a significant association between lower CSF Aβ42 and an increased risk of generalized epilepsy [6].

Previous studies have investigated the correlation between AD pathology and epilepsy [3,14–27] and have identified the underlying factors that have implications in this correlation. Aβ plaques and neurofibrillary tangles (NFTs), the two major hallmarks of AD, have been frequently linked to epilepsy [3,14,15,17]. Additionally, APOE ε4, the most significant genetic risk factor for sporadic AD, was also identified as a contributing factor for epilepsy [28]. Brain proteomics from epilepsy and AD patients have identified alterations in numerous proteins that interact with tau or are regulated by tau expression in epilepsy [20] although the exact mechanisms remain unclear. Other common factors between epilepsy and AD are changes in the glutamate and glutamine cycle [21,22], structural or functional defects of ion channel proteins [23], neuroinflammation [24], locus coeruleus degeneration [25] and metabolic alterations [26,27]. However, the molecular changes underlying the link between AD and epilepsy remain poorly understood. In this study, we analyzed high-throughput transcriptomic profiles from multiple AD cohorts and brain regions to investigate whether shared transcriptomic signatures can provide novel insights into the role epilepsy-causing genes in AD.

Materials and Methods

Study cohorts

The Knight Alzheimer Disease Research Center (Knight ADRC)

Summary statistics from the transcriptomic data from the parietal cortex from 255 sporadic AD participants and 23 controls were included in this study [29]. Total RNA was extracted from frozen parietal cortex tissue using a Tissue Lyser LT and purified using RNeasy Mini Kits (Qiagen). The Nanodrop 8000 (Thermo Scientific) and TapeStation 4200 (Agilent Technologies) were used to perform quality control of the RNA's concentration, purity, and degradation. The RNA integrity number (RIN) was calculated using an RNA 6000 Pico assay on a Bioanalyzer 2100 and TapeStation 4200 (Agilent Technologies). The DV200 value is defined as the percentage of nucleotides greater than 200nt. All cDNA libraries were prepared using a TruSeq Stranded Total RNA Sample Prep with Ribo-Zero Gold kit (Illumina) and sequenced on an Illumina

HiSeq 4000 using 2 × 151 paired-end reads at the McDonnell Genome Institute at Washington University in St. Louis.

The Mount Sinai Brain Bank (MSBB) study

The RNA-seq raw data from the MSBB study [30] was downloaded from the Synapse portal (syn3157743). Only data from the parahippocampal gyrus (PHG, BA36) were selected for this study. Briefly, RNA-seq libraries were prepared using the TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, California, USA). The rRNAs were depleted using the Ribo-Zero rRNA Removal Kit (human/mouse/rat) (Illumina). Single-end non-standard reads of 101 bp were generated by Illumina HiSeq 2500 (Illumina).

The Religious Orders Study and Memory and Aging Project (ROSMAP)

The RNA-seq raw data from the dorsolateral prefrontal cortex (DLPFC) from the ROSMAP Study [16] were downloaded from the Synapse portal (syn17008934). Briefly, RNA was extracted using Qiagen's miRNeasy mini kit (cat. no. 217004) and the RNase-free DNase Set (cat. no. 79254) and quantified by Nanodrop. Agilent Bioanalyzer evaluated quality. Library preparation was performed by poly-A selection followed by first strand-specific cDNA synthesis, then dUTP for second strand-specific cDNA synthesis, and fragmentation and Illumina adapter ligation for library construction. Illumina HiSeq generated paired-end read sequences with a length of 101 bp. Only No Cognitive Impairment (NCI) and AD with no other cause of cognitive impairment cases were used in this study [29].

Statistical Analysis

RNA-seq QC, alignment, and gene expression quantification

RNA-seq datasets from the three cohorts were processed and aligned using our in-house RNA-seq pipeline [29]. Reference genome GRCh38 and GENCODE 33 annotation, including the addition of ERCC spike-in annotations, were used. Before alignment, the quality of raw read sequences for all libraries was assessed using FastQC (v0.11.9) [31]. All read sequences were aligned to the human reference genome (GRCh38) using STAR (v.2.7.1a) [32]. Post-alignment quality was evaluated

using Picard tools (v.2.8.2) [33]. All samples that failed to pass the QC or were outliers were removed from the downstream analyses. Raw read counts for transcripts/genes were generated using STAR, and normalized gene expression levels were computed in Fragments Per Kilobase of transcript per Million mapped reads (FPKM) format as previously described [29].

Molecular profiling using an integrative clustering approach

AD molecular profiles were identified using iClusterBayes [34] , iClusterPlus R package (v1.22.0), [35]. Differential expression (DE) analyses were performed to compare cases in each AD profile to the control cases and the cases in other profiles using DESeq2 R package (v.1.22.2) [36]. All models were adjusted by sex, age at death, and the percentage of astrocytes and neurons. Only genes with expression > 0.5 CPM (count per million) in at least 25% of samples in either group being compared were retained for downstream analyses. All genes with FDR < 0.05 were considered differentially expressed genes (DEGs) [29]. This study only focuses on the DEGs between the worse cognitive profile and other sporadic AD cases in each cohort.

Pathways enrichment Analysis

Pathway analyses were performed using the EnrichR R package (v3.0) [180], using dysregulated genes to compare the worse cognitive profile of the sporadic AD cases across the three cohorts.

Brain Cell proportion based on single-cell transcriptomics

The estimated cellular population structure from gene expression data was computed using the CellMix R package (v1.6.2) [37]. The gene panel (marker genes expressed highly in specific cell types) and the machine learning model[38].

Results

Dysregulated epilepsy-causing genes in the multi-omics profile associated with *synaptic plasticity dysfunction* in AD

We have recently identified a subtype of AD cluster associated with significant dysregulation of synapse-related genes and pathways (from now on referred to as "*synaptic plasticity dysfunction or SPD*"). This subtype has clinical and neuropathological features correlates including significantly higher clinical dementia rating (CDR) at death, shorter survival after symptom onset, more severe neurodegeneration and astrogliosis, and decreased levels of metabolomic, suggesting an association with more severe cognitive profiles [29]. Here, we extended these analyses to study the correlation between the SPD profile and epilepsy-causing genes using transcriptomic profiles from AD patients (**Table 1**). We combined a list of 105 genes shown by the Epilepsy Foundation (https://www.epilepsy.com/causes/genetic) and Wang et al., 2017 [39] . We integrated it with the multi-omics integration analyses we performed previously [29].

In our previous work [29], we performed multiple differential gene expression analyses (see Material and Methods) to compare cases in the SPD to other AD cases (from now on referred to as "sporadic AD or sAD", **Fig. 1a-c**) as well as to the control cases in each AD cohort. We focused our analyses on the epilepsy-causing genes dysregulated between the SPD and the sAD profile. We first intersected the list of these genes with the list of dysregulated genes between the SPD and sAD profile in the three cohorts (**Fig. 1d**). Out of the 105 epilepsy-associated genes we selected, 45 (43%) were significantly dysregulated in the Knight ADRC SPD, 67 (64%) in the MSBB profile, and 41 (39%) in the ROSMAP profile (**Fig. 1d**). We then extracted the shared set of dysregulated genes across the three cohorts which included 16 epilepsy-associated genes (**Fig. 1d** and **Table 2**). Interestingly, 15 genes were consistently downregulated across the three cohorts, and only one gene (*CERS1*) was upregulated (**Fig. 1e-g**). Using RNA-seq data from human induced pluripotent stem cells (iPSC)-derived neurons, microglia, macrophages, and astrocytes (see Material and Methods), we observed that many of these genes were highly expressed in iPSC-derived neurons (**Fig. 2a**). These results were consistent with human brain gene expression generated from single-nuclei RNA-seq data from the parietal cortex of 67 Knight ADRC participants [40] (**Fig 2b**). Nine of these genes (*ARHGEF9, GABRA1, GABRB3,*

GABRG2, GRIN2A, HCN1, NECAP1, SCN1A, SCN8A) were mainly synaptic genes. **Table 2** shows the different epileptic phenotypes in each of the 16 genes involved. For instance, *CERS1* was shown to be involved in progressive myoclonic epilepsies (PME) [41,42], a group of heterogeneous disorders characterized by myoclonus, epileptic seizures, and progressive neurologic deterioration, which may include cognitive decline and ataxia [43]. This may indicate the correlation between the cognitive profile of AD and epilepsy since people with PME show a decline in cognitive function over time. We observed that nine genes: *UBA5, ARHGEF9, GABRB3, SCN8A, HCN1, SLC25A12, NECAP1, FGF12, GABRA1*, were involved in the Early infantile epileptic encephalopathy (EIEE) phenotype. These results suggest that the SPD of AD involved multiple epilepsy-causing genes with multiple epilepsy phenotypes.

Intersection between SPD cluster in AD and epilepsy-related pathways

We performed multiple biological pathway analyses and identified epilepsy-related pathways, including Glutamatergic synapse, Dopaminergic synapse, and GABAergic synapse (Fig 3a), all involved in various neurological and psychiatric disorders [44–49]. These pathways include genes encoding glutamate and GABA receptors (*GRIN2A, SLC1A2, PLCB1, GRIN2B, SCN1A, GABRB3, GABRA1, and GABRG2*) (**Fig 3b**). Additionally, we identified the Nicotine addiction pathway, which includes the genes *GABRB3*, *GABRA1*, *GRIN2A*, *GRIN2B*, *and GABRG2 (**Fig 3b**)*. Growing evidence shows that patients with epilepsy smoke at high, which may lead to an increase in seizure frequency [50–52]. Another significant pathway is circadian entrainment due to two glutamate ionotropic receptors (*GRIN2A*, *GRIN2B (***Fig 3b**). Increasing evidence shows the interaction between epilepsy and circadian rhythms [53].

Next, we looked at the Gene Ontology (GO) biological process pathways and observed that many were related to synaptic transmission, regulation, and glutamate signaling pathways (**Fig 3c**). These pathways were enriched in synaptic genes (**Fig 3d**). The sodium ion transport pathway is another significant one (**Fig 3c**). Many genetic mutations within genes that encode sodium channels have been identified in patients with epilepsy [54]. One of the top GO molecular function pathways identified were

channel activity pathways (**Fig 3e**), including voltage-gated sodium channel activity, GABA-gated chloride ion channel activity, ligand-gated anion channel activity, glutamate-gated calcium ion channel activity, chloride channel activity, which are implicated in the pathogenesis of epilepsy [54–58]. The top GO cellular component pathways were related to channel/receptor complex and synaptic membrane-related pathways (**Fig 3g-h**). Altogether, these results show that the SPD cluster of AD is significantly enriched in epilepsy-related pathways.

Epilepsy-causing gene dysregulation at multiple stages of AD

We selected the epilepsy-associated genes dysregulated in the SPD cluster and examined the effect size differences between the early-AD vs. control and the late-AD vs. control among the ROSMAP cohort (**Fig 4a-b**). Interestingly, we observed a concordant change of epilepsy-causing gene dysregulation in early and late AD compared to controls; however, the effect was more pronounced at later stages (**Fig 4b**, R^2_{adj} = 0.94, p = 1.1×10^{-15}, slope=1.2). This was consistent among 25 epilepsy genes including 23 down-regulated genes (*ARHGEF9*, *CACNB4*, *CDKL5*, *FGF12*, *GABRA1*, *GABRB3*, *GABRG2*, *GRIN2A*, *GUF1*, *HCN1*, *KCNQ3*, *MEF2C*, *NECAP1*, *NHLRC1*, *PPT1*, *PRICKLE1*, *SCARB2*, *SCN1A*, *SCN2A*, *SCN8A*, *ST3GAL5*, *STRADA*, *UBA5*) and two up-regulated genes (*CERS1* and *WWOX*) (**Fig 4b**). *WWOX* is associated with epileptic encephalopathy (EE) [59–63] (aka WOREE syndrome or WWOX-related epileptic encephalopathy), a severe type of epilepsy associated with severe cognitive and behavioral impairment starting in infancy and early childhood. Similarly, homozygous mutations in the *CERS1* gene have been linked to progressive myoclonic epilepsies Type 8 [41,42]. Three genes, *GABRG2*, *HCN1*, and *PRICKLE1*, had the most robust effect size (< -0.3 in both stages) among down-regulated genes (**Fig 4b**). Mutations in the *GABRG2* gene have been linked to multiple epilepsy syndromes, including simple febrile seizures (FS), childhood absence epilepsy (CAE), generalized epilepsy with febrile seizures plus (GEFS+), and Dravet syndrome (DS) [64]. Previous studies have shown that mutations in HCN1 can cause epilepsy through multiple HCN1 channel mechanisms, including loss-of-function (LOF) and gain-of-function (GOF) [65–

67]. Similarly, previous work has identified mutations in the *PRICKLE1* gene associated with autosomal recessive progressive myoclonus epilepsy-ataxia syndrome [68,69].

Discussion

The present study analyzed high-throughput transcriptomic data from sporadic AD cases and other AD cases with more severe cognitive profiles (SPD profile) across multiple AD cohorts and brain regions. We aimed to examine the relationship between molecularly defined profiles of AD and epilepsy-causing genes. Our findings corroborate the epilepsy-AD connection. In addition, we observed that these epilepsy-causing genes are mainly downregulated in AD earlier stages and correlate with AD progression. These results may indicate that epilepsy-causing genes are associated with both the onset and progression of AD, which could suggest that epileptic mechanisms might be present before or concurrently with the initial stages of AD. However, it remains uncertain which disorder precedes the other.

We found several epilepsy-causing genes/pathways dysregulated in the AD SPD profile, 16 of which were shared across the three cohorts of AD. Interestingly, 15 were consistently downregulated across the three cohorts, indicating that these genes probably encode proteins that present fundamental roles in cognitive function. We observed nine synaptic genes (*ARHGEF9*, *GABRA1*, *GABRB3*, *GABRG2*, *GRIN2A*, *HCN1*, *NECAP1*, *SCN1A*, *SCN8A*) highly expressed in iPSC-derived neurons, which may indicate synaptic dysfunction for both AD and epilepsy. *ARHGEF9* is a post-synaptic gene known to play a role in GABAergic synapses [70], and exhibits significant clinical heterogeneity, with epilepsy being a typical clinical phenotype [71–73]. *GABRA1*, *GABRB3*, and *GABRG2* are genes that encode GABAA receptor subunits. Disrupted GABAergic neurotransmission has been found in AD [74], and impaired GABAergic transmission might lead to the development of seizures in the early stages of AD through hippocampal hyperexcitability and an imbalance between excitation and inhibition [75]. We also identified *GRIN2A*, a gene encoding for the GluN2A subunit of the NMDA receptors [76]. Mutations in *GRIN2A* have been reported to be associated with multiple neurodevelopmental disorders, including epilepsy-aphasia spectrum

(EAS), developmental delay (DD), and intellectual disability (ID) [76–78]. *GRIN2A* is downregulated in AD samples [79]. These results suggest that *GRIN2A* may have protective roles, and its downregulation could contribute to the AD-epilepsy connection.

The decreased expression of *HCN1* was shown to be associated with epilepsy [80], visual function [81,82] and learning and memory [83,84]. *NECAP1* isa gene that encodes for a protein involved in clathrin-mediated endocytosis [85] ,playing a fundamental role in the early stages of this process. It is critical for synaptic vesicle recycling, a key process in neurotransmission [86,87]. The loss of function of *NECAP1* results in severe infantile epileptic encephalopathy [85,88–90]. *SCN1A* and *SCN8A* encode two of the four voltage-gated sodium channels (VGSCs) primarily expressed in the central nervous system. Beyond their well-known association with epilepsy [91,92], *SCN1A* and *SCN8A* have also been frequently associated with ID and cognitive impairment [93–96], even in the absence of seizures [97,98]. Clinical screening of a family with Dravet Syndrome (DS) recently found an *SCN1A* missense mutation [99]. Years later, one family member, initially diagnosed with generalized epilepsy without ID, was diagnosed with AD, and a neuropathological examination confirmed the AD diagnosis by identifying NFT and Aβ pathology [99]. These findings align with our findings and suggest the connection between AD and DS patients, which often face early mortality and cognitive deficits.

We also identified *KCNQ3*, which encodes for the voltage-gated potassium channel subfamily Q member 3. Mutations in *KCNQ3* are associated with various forms of epilepsy, including benign familial neonatal epilepsy, infantile epilepsy, and epileptic encephalopathy with ID and cortical visual impairment [100–103]. Moreover, we identified *UBA5*, *PPT1*, *SLC25A12*, *MEF2C*, and *FGF12*, all of which have been reported to play a role in epilepsy and AD [104–125]. Notably, we found downregulation of *MEF2C*, which maintains proper physiological processes in multiple brain cell types [117].

Interestingly, *CERS1* was the only gene upregulated in the SPD cluster, which encodes Ceramide Synthase 1, an enzyme involved in ceramide biosynthesis [126]. It catalyzes the synthesis of C18 ceramide and is expressed in many tissues, predominantly in the CNS [126,127]. *CERS1* deficiency causes Progressive Myoclonic Epilepsy [41,42]. Increased cerebrospinal fluid levels and plasma C18 ceramide are associated with elevated AD markers, worse disease progression, and inflammation [128–130]. The decreasing plasma ceramide C18 concentration is also associated with improved cognitive performance [131]. Moreover, chronic insulin resistance, another feature of AD [132], increases ceramide production, further impairing insulin signaling and creating a vicious cycle with significant implications for AD [133]. *CERS1* is regulated by the PI3K/AKT signaling pathway [134], which is dysregulatedin AD [135]. Interestingly, disturbed insulin signaling, particularly the PI3K/AKT pathway, has also been proposed in epilepsy [19,136,137]. Hence, alterations in the regulation of *CERS1* and its function in producing ceramide emphasize the potential importance of ceramide metabolism in both epilepsy and AD.

We found larger effect sizes in epilepsy-causing genes at later AD stages which indicate that AD patients are at an increased risk for seizures in advanced disease stages [138]. Corroborating our findings, a recent study reported that subclinical epileptiform activity (SEA) increased in the AD continuum compared to controls, with its presence correlating with AD progression [139]. In these AD cases, SEA was associated with more severe visuospatial and attention impairments [139].

In a recent study, ~90% of proteins altered in the hippocampus of epilepsy patients were also significantly changed in advanced AD [20]. Most of synapse and mitochondrial proteins were altered in the same direction in both conditions; many ribosomal proteins were changed in opposite directions [20]. Interestingly, some proteins reported by the authors overlap with the findings in our study, including *SCN2A* decreased in epilepsy and AD [20]. *SLC25A22*, another SLC25 mitochondrial carrier family member, was reduced in both disorders [20], aligning with the downregulation of *SLC25A12* observed in our study. *SCN2A*, one of the four VGSCs primarily expressed

in the CNS, was decreased in their research [20], along with the downregulation of *SCN1A* and *SCN8A* observed here. These findings highlight common molecular pathways and potential therapeutic targets shared between epilepsy and AD, particularly in synaptic and mitochondrial function.

Although dysregulated epilepsy-causing genes might be unleashing AD pathogenesis, AD pathology may be triggering seizures along with disease onset. Thus, the dysregulation of epilepsy-associated genes could occur after AD pathology initiates. These two hypotheses underscore the complexity of the relationship between epilepsy and AD. A third and more plausible hypothesis is that the interrelation between the two suggests that either condition could precede the other, and the onset may vary between individuals.

Conclusion

The intricate interaction between epilepsy and AD reveals a two-way relationship influenced by common genetic pathways and overlapping pathophysiological mechanisms. Our study shows that epilepsy-causing genes are disrupted in AD, particularly in later stages, indicating a potential role in the progression of the disease. These findings highlight the possibility that mechanisms involved in epilepsy may precede or co-occur with early AD pathology. At the same time, changes associated with AD may also worsen neuronal hyperexcitability and lead to seizures. The reduced transcript levels of synaptic genes such as *ARHGEF9*, *GABRA1*, *GABRB3*, and others indicate their crucial roles in cognitive function and potential association with epilepsy and AD. These findings support previous research linking disturbed GABAergic and glutamatergic neurotransmission to AD development and suggest that changes in these pathways contribute to the observed decline in cognitive function. Additionally, identifying down-regulated genes such as *SCN1A*, *SCN8A*, and *HCN1* emphasizes their dual roles in controlling neuronal excitability and synaptic function, implicating them in the progression of epilepsy and AD. Our results highlight the importance of genetic findings in the clinical context and indicate that AD patients with epilepsy tend to experience more severe cognitive impairments and faster disease progression. This

supports clinical observations of increased seizure susceptibility in different stages of AD, particularly in advanced phases. It underscores the importance of early detection and management of epilepsy in AD patients. In addition, the shared genetic pathways between epilepsy and AD suggest potential therapeutic targets that could benefit both conditions. This highlights the necessity for integrated treatment strategies. Our findings contribute to a deeper understanding of the connection between epilepsy and AD, although the exact order in which they overlap remains unclear. We believe that the development of epilepsy and AD may vary among individuals, underscoring the importance of personalized approaches, particularly leveraging genetic technology. The comprehension of these mechanisms will facilitate the development of targeted treatments addressing shared genetic vulnerabilities, thereby potentially improving outcomes for individuals affected by both epilepsy and AD. The results of the Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) trial provide a hint that stratification based on the epileptiform phenotype in AD could be crucial, particularly for developing targeted therapies to reduce network hyperexcitability.

Data Statement

Transcriptomics raw data from MSBB study are publicly available at Synapse under Synapse IDs syn3157743 (https://www.synapse.org/#!Synapse:syn3157743). Transcriptomics raw data from ROSMAP study are publicly available at Synapse under Synapse IDs syn17008934 (https://www.synapse.org/#!Synapse:syn17008934).

Funding

This work was supported by grants from the National Institutes of Health: R01NS118146 (BAB), R21NS127211 (BAB), and K25AG083057 (AME). The BIDMC 2023 Translational Research Hub Spark Grant Award (BAB and SB). SSA (a PhD student from the University of São Paulo) was supported by Brazil grants CAPES (Finance Code 001) and FAPESP (17/21155-3). NGC (SSA Adviser) received Brazil Grants (CNPq 1A Research Fellowship #302500/2022-7 and FAPESP #2019/05957-8).

CRediT authorship contribution statement

AEM data curation, formal analysis, methodology, software, original draft writing, review & editing. SB participated in funding acquisition. SB, MS, and DP resources and conceptualization. SSA and NGC participated in writing, reviewing & editing the first and last versions of the manuscript. BAB participated in conceptualization, funding acquisition, methodology, project administration, supervision, writing – review & editing of the first and last versions of the manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

We thank all the participants, their families, the many involved institutions, and their staff, whose help and participation made this work possible.

References

1. Lam AD, Shafi MM. Towards a coherent view of network hyperexcitability in Alzheimer's disease. Brain. 2022;145(2):423–5.

2. Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer's disease: causes and clinical relevance. The Lancet Neurology. 2017;16(4):311–22.

3. Canet G, Zub E, Zussy C, Hernandez C, Blaquiere M, Garcia V, et al. Seizure activity triggers tau hyperphosphorylation and amyloidogenic pathways. Epilepsia. 2022 Apr;63(4):919–35.

4. Dun C, Zhang Y, Yin J, Su B, Peng X, Liu L. Bi-directional associations of epilepsy with dementia and Alzheimer's disease: a systematic review and meta-analysis of longitudinal studies. Age and ageing. 2022;51(3):afac010.

5. Beghi E, Giussani G, Costa C, DiFrancesco JC, Dhakar M, Leppik I, et al. The epidemiology of epilepsy in older adults: A narrative review by the ILAE Task Force on Epilepsy in the Elderly. Epilepsia. 2023 Mar;64(3):586–601.

6. Fang Y, Si X, Wang J, Wang Z, Chen Y, Liu Y, et al. Alzheimer Disease and Epilepsy: A Mendelian Randomization Study. Neurology [Internet]. 2023 Jul 25 [cited 2024 Nov 7];101(4). Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000207423

7. Tan Z, Wang FY, Wu WP, Wu JC, Wang L. Bidirectional relationship between late-onset epilepsy (LOE) and dementia: A systematic review and meta-analysis of cohort studies. Epilepsy & Behavior. 2024;153:109723.

8. Zawar I, Kapur J. Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype? Alzheimer's & Dementia. 2023 Jun;19(6):2697–706.

9. Zhang D, Chen S, Xu S, Wu J, Zhuang Y, Cao W, et al. The clinical correlation between Alzheimer's disease and epilepsy. Frontiers in Neurology. 2022;13:922535.

10. Chai X, Xiao Z, Zhao Q, Wang J, Ding D, Zhang J. Cognitive impairment as a comorbidity of epilepsy in older adults: Analysis of global and domain specific cognition. Epileptic Disorders. 2023 Feb;25(1):65–73.

11. Tai XY, Torzillo E, Lyall DM, Manohar S, Husain M, Sen A. Association of dementia risk with focal epilepsy and modifiable cardiovascular risk factors. JAMA neurology. 2023;80(5):445–54.

12. Zawar I, Quigg M, Manning C, Kapur J. Seizures in Dementia are Associated with Worse Clinical Outcomes, Higher Mortality and Shorter Lifespans (P3-1.001). Neurology. 2023 Apr 25;100(17_supplement_2):1774.

13. Subota A, Pham T, Jetté N, Sauro K, Lorenzetti D, Holroyd□Leduc J. The association between dementia and epilepsy: A systematic review and meta□analysis. Epilepsia. 2017 Jun;58(6):962–72.

14. Aroor A, Nguyen P, Li Y, Das R, Lugo JN, Brewster AL. Assessment of tau phosphorylation and β□amyloid pathology in human drug□resistant epilepsy. Epilepsia Open. 2023 Jun;8(2):609–22.

15. Gourmaud S, Shou H, Irwin DJ, Sansalone K, Jacobs LM, Lucas TH, et al. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain. 2020;143(1):191–209.

16. A Bennett D, A Schneider J, Arvanitakis Z, S Wilson R. Overview and findings from the religious orders study. Current Alzheimer Research. 2012;9(6):628–45.

17. Romoli M, Sen A, Parnetti L, Calabresi P, Costa C. Amyloid-β: a potential link between epilepsy and cognitive decline. Nature Reviews Neurology. 2021;17(8):469–85.

18. Alves SS, Da Silva Junior RMP, Delfino-Pereira P, Pereira MGAG, Vasconcelos I, Schwaemmle H, et al. A Genetic Model of Epilepsy with a Partial Alzheimer's Disease-Like Phenotype and Central Insulin Resistance. Mol Neurobiol. 2022 Jun;59(6):3721–37.

19. Alves SS, De Oliveira JAC, Lazarini-Lopes W, Servilha-Menezes G, Grigório-de-Sant'Ana M, Del Vecchio F, et al. Audiogenic Seizures in the Streptozotocin-Induced Rat Alzheimer's Disease Model. JAD. 2023 Aug 1;94(3):1179–96.

20. Leitner D, Pires G, Kavanagh T, Kanshin E, Askenazi M, Ueberheide B, et al. Similar brain proteomic signatures in Alzheimer's disease and epilepsy. Acta Neuropathol. 2024 Jun;147(1):27.

21. Eid T, Gruenbaum SE, Dhaher R, Lee TSW, Zhou Y, Danbolt NC. The Glutamate–Glutamine Cycle in Epilepsy. In: Schousboe A, Sonnewald U, editors. The Glutamate/GABA-Glutamine Cycle [Internet]. Cham: Springer International Publishing; 2016 [cited 2024 Nov 7]. p. 351–400. (Advances in Neurobiology; vol. 13). Available from: http://link.springer.com/10.1007/978-3-319-45096-4_14

22. Walton HS, Dodd PR. Glutamate–glutamine cycling in Alzheimer's disease. Neurochemistry international. 2007;50(7–8):1052–66.

23. Tang T, Li X, Yu E, Li M, Pan X. Identification of common core ion channel genes in epilepsy and Alzheimer's disease. Ir J Med Sci. 2024 Feb;193(1):417–24.

24. Liew Y, Retinasamy T, Arulsamy A, Ali I, Jones NC, O'Brien TJ, et al. Neuroinflammation: A common pathway in Alzheimer's disease and epilepsy. Journal of Alzheimer's Disease. 2023;94(s1):S253–65.

25. Giorgi FS, Saccaro LF, Busceti CL, Biagioni F, Fornai F. Epilepsy and Alzheimer's Disease: Potential mechanisms for an association. Brain Research Bulletin. 2020;160:107–20.

26. He M, Kolesar TA, Goertzen AL, Ng MC, Ko JH. Do Epilepsy Patients with Cognitive Impairment Have Alzheimer's Disease-like Brain Metabolism? Biomedicines. 2023;11(4):1108.

27. Rho JM, Boison D. The metabolic basis of epilepsy. Nature Reviews Neurology. 2022;18(6):333–47.

28. Liang Y, Zhou Z, Wang H, Cheng X, Zhong S, Zhao C. Association of apolipoprotein E genotypes with epilepsy risk: A systematic review and meta-analysis. Epilepsy & Behavior. 2019;98:27–35.

29. Eteleeb AM, Novotny BC, Tarraga CS, Sohn C, Dhungel E, Brase L, et al. Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease. PLoS biology. 2024;22(4):e3002607.

30. Wang M, Beckmann ND, Roussos P, Wang E, Zhou X, Wang Q, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Scientific data. 2018;5(1):1–16.

31. Andrews S. FastQC: a quality control tool for high throughput sequence data. Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom; 2010.

32. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.

33. Picard Toolkit." 2019. Broad Institute, GitHub Repository. https://broadinstitute.github.io/picard/; Broad Institute.

34. Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018;19(1):71–86.

35. Mo Q, Shen R. iClusterPlus: integrative clustering of multiple genomic data sets. 2013;

36. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology. 2014;15(12):1–21.

37. Gaujoux R, Seoighe C. CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics. 2013;29(17):2211–2.

38. Li Z, Del-Aguila JL, Dube U, Budde J, Martinez R, Black K, et al. Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome medicine. 2018;10(1):1–19.

39. Wang J, Lin ZJ, Liu L, Xu HQ, Shi YW, Yi YH, et al. Epilepsy-associated genes. Seizure. 2017;44:11–20.

40. Brase L, You SF, D'Oliveira Albanus R, Del-Aguila JL, Dai Y, Novotny BC, et al. Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. Nature communications. 2023;14(1):2314.

41. Vanni N, Fruscione F, Ferlazzo E, Striano P, Robbiano A, Traverso M, et al. Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Annals of Neurology. 2014 Aug;76(2):206–12.

42. Junior C de OG, Vale TC, de Melo Afonso CO, Kok F, Pedroso JL, Barsottini OG. Progressive myoclonic epilepsy type 8 due to CERS1 deficiency: a novel mutation with prominent ataxia. Movement disorders clinical practice. 2018;5(3):330.

43. Kälviäinen R. Progressive Myoclonus Epilepsies. Semin Neurol. 2015 Jun 10;35(03):293–9.

44. Chen TS, Huang TH, Lai MC, Huang CW. The role of glutamate receptors in epilepsy. Biomedicines. 2023;11(3):783.

45. Bozzi Y, Borrelli E. The role of dopamine signaling in epileptogenesis. Frontiers in cellular neuroscience. 2013;7:157.

46. Tripathi PP, Bozzi Y. The role of dopaminergic and serotonergic systems in neurodevelopmental disorders: a focus on epilepsy and seizure susceptibility. BioImpacts: BI. 2015;5(2):97.

47. Rezaei M, Sadeghian A, Roohi N, Shojaei A, Mirnajafi-Zadeh J. Epilepsy and dopaminergic system. Physiology and Pharmacology. 2017;21(1):1–14.

48. Starr MS. The role of dopamine in epilepsy. Synapse. 1996 Feb;22(2):159–94.

49. Treiman DM. GABAergic Mechanisms in Epilepsy. Epilepsia. 2001 Jul;42(s3):8–12.

50. Narrett JA, Khan W, Funaro MC, Moeller JJ. How do smoking, vaping, and nicotine affect people with epilepsy and seizures? A scoping review protocol. Plos one. 2023;18(7):e0288120.

51. Elliott JO, Lu B, Moore JL, McAuley JW, Long L. Exercise, diet, health behaviors, and risk factors among persons with epilepsy based on the California Health Interview Survey, 2005. Epilepsy & Behavior. 2008;13(2):307–15.

52. Sapkota S. Prevalence and trends in cigarette smoking among adults with epilepsy—United States, 2010–2017. MMWR Morbidity and Mortality Weekly Report [Internet]. 2020 [cited 2024 Apr 19];69. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6947a5.htm

53. Jin B, Aung T, Geng Y, Wang S. Epilepsy and Its Interaction With Sleep and Circadian Rhythm. Front Neurol. 2020 May 8;11:327.

54. Kaplan DI, Isom LL, Petrou S. Role of sodium channels in epilepsy. Cold Spring Harbor perspectives in medicine. 2016;6(6):a022814.

55. Cain SM, Snutch TP. Voltage-gated calcium channels in epilepsy. Jasper's Basic Mechanisms of the Epilepsies [Internet] 4th edition [Internet]. 2012 [cited 2024 Apr 19]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK98147/

56. Menezes LFS, Sabiá Júnior EF, Tibery DV, Carneiro LDA, Schwartz EF. Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review. Front Pharmacol. 2020 Aug 18;11:1276.

57. Agbo J, Ibrahim ZG, Magaji SY, Mutalub YB, Mshelia PP, Mhyha DH. Therapeutic efficacy of voltage-gated sodium channel inhibitors in epilepsy. Acta Epileptologica. 2023 Jun 28;5(1):16.

58. Brunklaus A, Lal D. Sodium channel epilepsies and neurodevelopmental disorders: from disease mechanisms to clinical application. Develop Med Child Neuro. 2020 Jul;62(7):784–92.

59. Al Baradie R, Mir A, Alsaif A, Ali M, Al Ghamdi F, Bashir S, et al. Epilepsy in patients with *WWOX* related epileptic encephalopathy (WOREE) syndrome. Epileptic Disorders. 2022 Aug;24(4):697–712.

60. Oliver KL, Trivisano M, Mandelstam SA, De Dominicis A, Francis DI, Green TE, et al. *WWOX* developmental and epileptic encephalopathy: Understanding the epileptology and the mortality risk. Epilepsia. 2023 May;64(5):1351–67.

61. Oliver KL, Trivisano M, Mandelstam SA, De Dominicis A, Francis DI, Green TE, et al. *WWOX* developmental and epileptic encephalopathy: Understanding the epileptology and the mortality risk. Epilepsia. 2023 May;64(5):1351–67.

62. Repudi S, Steinberg DJ, Elazar N, Breton VL, Aquilino MS, Saleem A, et al. Neuronal deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin defects. Brain. 2021;144(10):3061–77.

63. Cheng YY, Chou YT, Lai FJ, Jan MS, Chang TH, Jou IM, et al. Wwox deficiency leads to neurodevelopmental and degenerative neuropathies and glycogen synthase kinase 3β-mediated epileptic seizure activity in mice. acta neuropathol commun. 2020 Dec;8(1):6.

64. Kang JQ, Macdonald RL. Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to Dravet syndrome. JAMA neurology. 2016;73(8):1009–16.

65. Nava C, Dalle C, Rastetter A, Striano P, de Kovel CG, Nabbout R, et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nature genetics. 2014;46(6):640–5.

66. Xie C, Liu F, He H, He F, Mao L, Wang X, et al. Novel HCN1 mutations associated with epilepsy and impacts on neuronal excitability. Frontiers in Molecular Neuroscience. 2022;15:870182.

67. Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacological reviews. 2018;70(1):142–73.

68. Bassuk AG, Wallace RH, Buhr A, Buller AR, Afawi Z, Shimojo M, et al. A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. The American Journal of Human Genetics. 2008;83(5):572–81.

69. Mastrangelo M, Tolve M, Martinelli M, Di Noia SP, Parrini E, Leuzzi V. *PRICKLE1* related early onset epileptic encephalopathy. American J of Med Genetics Pt A. 2018 Dec;176(12):2841–5.

70. Soykan T, Schneeberger D, Tria G, Buechner C, Bader N, Svergun D, et al. A conformational switch in collybistin determines the differentiation of inhibitory postsynapses. The EMBO Journal. 2014 Sep 17;33(18):2113–33.

71. Bernardo P, Cuccurullo C, Rubino M, De Vita G, Terrone G, Bilo L, et al. X-Linked Epilepsies: A Narrative Review. International Journal of Molecular Sciences. 2024;25(7):4110.

72. Yang H, Liao H, Gan S, Xiao T, Wu L. *ARHGEF9* gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration. Molec Gen & Gen Med. 2022 Jul;10(7):e1967.

73. Yao R, Zhang Y, Liu J, Wang J, Xu Y, Li N, et al. Clinical and Molecular Characterization of Three Novel ARHGEF9 Mutations in Patients with Developmental Delay and Epilepsy. J Mol Neurosci. 2020 Jun;70(6):908–15.

74. Li Y, Sun H, Chen Z, Xu H, Bu G, Zheng H. Implications of GABAergic neurotransmission in Alzheimer's disease. Frontiers in aging neuroscience. 2016;8:31.

75. Mao R, Hu M, Liu X, Ye L, Xu B, Sun M, et al. Impairments of GABAergic transmission in hippocampus mediate increased susceptibility of epilepsy in the early stage of Alzheimer's disease. Cell Commun Signal. 2024 Feb 22;22(1):147.

76. Shepard N, Baez-Nieto D, Iqbal S, Kurganov E, Budnik N, Campbell AJ, et al. Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders. Scientific reports. 2024;14(1):2798.

77. Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nature genetics. 2013;45(9):1061–6.

78. Strehlow V, Heyne HO, Vlaskamp DR, Marwick KF, Rudolf G, De Bellescize J, et al. GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain. 2019;142(1):80–92.

79. Ceylan H. Integrated Bioinformatics Analysis to Identify Alternative Therapeutic Targets for Alzheimer's Disease: Insights from a Synaptic Machinery Perspective. J Mol Neurosci. 2022 Feb;72(2):273–86.

80. Lin W, Qin J, Ni G, Li Y, Xie H, Yu J, et al. Downregulation of hyperpolarization activated cyclic nucleotide gated channels (HCN) in the hippocampus of patients with medial temporal lobe epilepsy and hippocampal sclerosis (MTLE HS). Hippocampus. 2020 Oct;30(10):1112–26.

81. Mckenzie CE, Ho CJ, Forster IC, Soh MS, Phillips AM, Chang YC, et al. Impaired color recognition in HCN1 epilepsy: a single case report. Frontiers in Neurology. 2022;13:834252.

82. Zhao D, Pinares-Garcia P, McKenzie CE, Bleakley LE, Forster IC, Wong VH, et al. Retinal dysfunction in a mouse model of HCN1 genetic epilepsy. Journal of Neuroscience. 2023;43(12):2199–209.

83. Chen X, Zhang Q, Su Y, Zhao W, Li Y, Du B, et al. Evidence for the contribution of HCN1 gene polymorphism (rs1501357) to working memory at both behavioral and neural levels in schizophrenia patients and healthy controls. Schizophrenia. 2022;8(1):66.

84. Nolan MF, Malleret G, Dudman JT, Buhl DL, Santoro B, Gibbs E, et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell. 2004;119(5):719–32.

85. Alazami AM, Hijazi H, Kentab AY, Alkuraya FS. NECAP1 loss of function leads to a severe infantile epileptic encephalopathy. Journal of Medical Genetics. 2014;51(4):224–8.

86. Murshid A, Srivastava A, Kumar R, Presley JF. Characterization of the localization and function of NECAP 1 in neurons. Journal of Neurochemistry. 2006 Sep;98(6):1746–62.

87. Ritter B, Murphy S, Dokainish H, Girard M, Gudheti MV, Kozlov G, et al. NECAP 1 regulates AP-2 interactions to control vesicle size, number, and cargo during clathrin-mediated endocytosis. PLoS biology. 2013;11(10):e1001670.

88. Alsahli S, Al Twaijri W, Al Mutairi F. Confirming the pathogenicity of *NECAP 1* in early onset epileptic encephalopathy. Epilepsia Open. 2018 Dec;3(4):524–7.

89. Chouery E, Mehawej C, Sabbagh S, Bleik J, Megarbane A. Early infantile epileptic encephalopathy related to *NECAP1* : Clinical delineation of the disease and review. Euro J of Neurology. 2022 Aug;29(8):2486–92.

90. Mizuguchi T, Nakashima M, Moey LH, Ch'ng GS, Khoo TB, Mitsuhashi S, et al. A novel homozygous truncating variant of NECAP1 in early infantile epileptic encephalopathy: the second case report of EIEE21. Journal of Human Genetics. 2019;64(4):347–50.

91. Escayg A, Goldin AL. Sodium channel *SCN1A* and epilepsy: Mutations and mechanisms. Epilepsia. 2010 Sep;51(9):1650–8.

92. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Frontiers in neurology. 2015;6:104.

93. Gardella E, Marini C, Trivisano M, Fitzgerald MP, Alber M, Howell KB, et al. The phenotype of *SCN8A* developmental and epileptic encephalopathy. Neurology [Internet]. 2018 Sep 18 [cited 2024 Nov 7];91(12). Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000006199

94. Guerrini R, Falchi M. Dravet syndrome and *SCN1A* gene mutation related epilepsies: cognitive impairment and its determinants. Develop Med Child Neuro. 2011 Apr;53(s2):11–5.

95. Liu Y, Schubert J, Sonnenberg L, Helbig KL, Hoei-Hansen CE, Koko M, et al. Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability. Brain. 2019;142(2):376–90.

96. Riga MS, Pérez-Fernández M, Miquel-Rio L, Paz V, Campa L, Martínez-Losa M, et al. Scn1a haploinsufficiency in the prefrontal cortex engages to cognitive impairment and depressive phenotype. Brain. 2024;awae167.

97. Bender AC, Natola H, Ndong C, Holmes GL, Scott RC, Lenck-Santini PP. Focal Scn1a knockdown induces cognitive impairment without seizures. Neurobiology of disease. 2013;54:297–307.

98. Wagnon JL, Barker BS, Ottolini M, Park Y, Volkheimer A, Valdez P, et al. Loss-of-function variants of *SCN8A* in intellectual disability without seizures. Neurol Genet. 2017 Aug;3(4):e170.

99. Sierra-Marcos A, Ribosa-Nogué R, Vidal-Robau N, Aldecoa I, Turón E, Rodríguez-Santiago B, et al. Inherited SCN1A missense mutation in a Dravet Syndrome family: Neuropathological correlation, family screening and implications for adult carriers. Epilepsy Research. 2024;199:107266.

100. Nardello R, Mangano GD, Miceli F, Fontana A, Piro E, Salpietro V. Benign familial infantile epilepsy associated with *KCNQ3* mutation: a rare occurrence or an underestimated event? Epileptic Disorders. 2020 Dec;22(6):807–10.

101. Portale A, Comella M, Salomone G, Di Nora A, Marino L, Leonardi R, et al. The Spectrum of KCNQ2- and KCNQ3-Related Epilepsy. Journal of Pediatric Neurology. 2023 Jun;21(03):203–11.

102. Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends in neurosciences. 2000;23(9):393–8.

103. Soldovieri MV, Ambrosino P, Mosca I, Servettini I, Pietrunti F, Belperio G, et al. *De novo* variants in *KCNA3* cause developmental and epileptic encephalopathy. Annals of Neurology. 2024 Feb;95(2):365–76.

104. Low KJ, Baptista J, Babiker M, Caswell R, King C, Ellard S, et al. Hemizygous UBA5 missense mutation unmasks recessive disorder in a patient with infantile-onset encephalopathy, acquired microcephaly, small cerebellum, movement disorder and severe neurodevelopmental delay. European journal of medical genetics. 2019;62(2):97–102.

105. Gadhave K, Kumar D, Uversky VN, Giri R. A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. Medicinal Research Reviews. 2021 Sep;41(5):2689–745.

106. Bravo CP, Giani AM, Madero-Perez J, Zhao Z, Wan Y, Samelson AJ, et al. Human iPSC 4R tauopathy model uncovers modifiers of tau propagation. Cell. 2024;187(10):2446–64.

107. Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp Biol Med (Maywood). 2011 Mar;236(3):268–76.

108. Yan T, Heckman MG, Craver EC, Liu CC, Rawlinson BD, Wang X, et al. The UFMylation pathway is impaired in Alzheimer's disease. bioRxiv. 2024;2024–05.

109. Gupta P, Soyombo AA, Atashband A, Wisniewski KE, Shelton JM, Richardson JA, et al. Disruption of *PPT1* or *PPT2* causes neuronal ceroid lipofuscinosis in knockout mice. Proc Natl Acad Sci USA. 2001 Nov 20;98(24):13566–71.

110. Simonati A, Williams RE. Neuronal ceroid lipofuscinosis: the multifaceted approach to the clinical issues, an overview. Frontiers in neurology. 2022;13:811686.

111. Zhang X, Wang M, Feng B, Zhang Q, Tong J, Wang M, et al. Seizures in PPT1 knock-in mice are associated with inflammatory activation of microglia. International Journal of Molecular Sciences. 2022;23(10):5586.

112. Benussi L, Longobardi A, Kocoglu C, Carrara M, Bellini S, Ferrari C, et al. Investigating the endo-lysosomal system in major neurocognitive disorders due to Alzheimer's disease, frontotemporal lobar degeneration and lewy body disease: Evidence for SORL1 as a cross-disease gene. International journal of molecular sciences. 2021;22(24):13633.

113. Romero SC, Eteleeb AM, Nykanen N, O'Dell K, Nunez M, Harari O, et al. circRNAs mediate the effect of chronic lysosomal dysfunction on Alzheimer's disease pathology. Alzheimer's & Dementia. 2023 Dec;19(S13):e072168.

114. Falk MJ, Li D, Gai X, McCormick E, Place E, Lasorsa FM, et al. AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate. In: Zschocke J, Gibson KM, Brown G, Morava E, Peters V, editors. JIMD Reports, Volume 14 [Internet].

Berlin, Heidelberg: Springer Berlin Heidelberg; 2014 [cited 2024 Nov 7]. p. 77–85. (JIMD Reports; vol. 14). Available from: http://link.springer.com/10.1007/8904_2013_287

115. Mir A, Almudhry M, Alghamdi F, Albaradie R, Ibrahim M, Aldurayhim F, et al. SLC gene mutations and pediatric neurological disorders: diverse clinical phenotypes in a Saudi Arabian population. Hum Genet. 2022 Jan;141(1):81–99.

116. Taheri M, Pourtavakoli A, Eslami S, Ghafouri-Fard S, Sayad A. Assessment of expression of calcium signaling related lncRNAs in epilepsy. Scientific Reports. 2023;13(1):17993.

117. Assali A, Harrington AJ, Cowan CW. Emerging roles for MEF2 in brain development and mental disorders. Current opinion in neurobiology. 2019;59:49–58.

118. Zhang Z, Zhao Y. Progress on the roles of MEF2C in neuropsychiatric diseases. Mol Brain. 2022 Dec;15(1):8.

119. Burton TR, Dibrov A, Kashour T, Amara FM. Anti-apoptotic wild-type Alzheimer amyloid precursor protein signaling involves the p38 mitogen-activated protein kinase/MEF2 pathway. Molecular brain research. 2002;108(1–2):102–20.

120. Ohori S, Miyauchi A, Osaka H, Lourenco CM, Arakaki N, Sengoku T, et al. Biallelic structural variations within FGF12 detected by long-read sequencing in epilepsy. Life Science Alliance [Internet]. 2023 [cited 2024 Nov 7];6(8). Available from: https://www.life-science-alliance.org/content/6/8/e202302025.abstract

121. Saleem NM, Chencheri N, Thomas S, Alexander G, Madathil B. Early-Onset Epileptic Encephalopathy Responsive to Phenytoin: A Diagnostic Clue for Fibroblast Growth Factor 12 Mutation. Cureus [Internet]. 2024 [cited 2024 Nov 7];16(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924931/

122. Takeguchi R, Haginoya K, Uchiyama Y, Fujita A, Nagura M, Takeshita E, et al. Two Japanese cases of epileptic encephalopathy associated with an FGF12 mutation. Brain and Development. 2018;40(8):728–32.

123. Willemsen MH, Goel H, Verhoeven JS, Braakman HMH, De Leeuw N, Freeth A, et al. Epilepsy phenotype in individuals with chromosomal duplication encompassing *FGF12*. Epilepsia Open. 2020 Jun;5(2):301–6.

124. Liao W, Luo H, Ruan Y, Mai Y, Liu C, Chen J, et al. Identification of candidate genes associated with clinical onset of Alzheimer's disease. Frontiers in Neuroscience. 2022;16:1060111.

125. Zhang MW, Liang XY, Wang J, Gao LD, Liao HJ, He YH, et al. Epilepsy-associated genes: an update. Seizure: European Journal of Epilepsy. 2024;116:4–13.

126. Wegner MS, Schiffmann S, Parnham MJ, Geisslinger G, Grösch S. The enigma of ceramide synthase regulation in mammalian cells. Progress in lipid research. 2016;63:93–119.

127. Ruan Y, Lv W, Li S, Cheng Y, Wang D, Zhang C, et al. Identification of telomere-related genes associated with aging-related molecular clusters and the construction of a diagnostic model in Alzheimer's disease based on a bioinformatic analysis. Computers in Biology and Medicine. 2023;159:106922.

128. Liu X, Jin Y, Cheng X, Song Q, Wang Y, He L, et al. The relevance between abnormally elevated serum ceramide and cognitive impairment in Alzheimer's disease model mice and its mechanism. Psychopharmacology. 2024 Mar;241(3):525–42.

129. Teitsdottir UD, Halldorsson S, Rolfsson O, Lund SH, Jonsdottir MK, Snaedal J, et al. Cerebrospinal fluid C18 ceramide associates with markers of Alzheimer's disease and inflammation at the pre-and early stages of dementia. Journal of Alzheimer's Disease. 2021;81(1):231–44.

130. Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS medicine. 2018;15(1):e1002482.

131. Saleem M, Herrmann N, Dinoff A, Mielke MM, Oh PI, Shammi P, et al. A lipidomics approach to assess the association between plasma sphingolipids and verbal memory performance in coronary artery disease patients undertaking cardiac rehabilitation: A C18: 0 signature for cognitive response to exercise. Journal of Alzheimer's Disease. 2017;60(3):829–41.

132. Alves SS, Silva-Junior RMP da, Servilha-Menezes G, Homolak J, Šalković-Petrišić M, Garcia-Cairasco N. Insulin resistance as a common link between current Alzheimer's disease hypotheses. Journal of Alzheimer's Disease. 2021;82(1):71–105.

133. de la Monte SM, Re E, Longato L, Tong M. Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease. Journal of Alzheimer's Disease. 2012;30(s2):S217–29.

134. Wang J, Zhang J, Ma D, Li X. The Potential Role of CERS1 in Autophagy Through PI3K/AKT Signaling Pathway in Hypophysoma. Technol Cancer Res Treat. 2020 Jan 1;19:1533033820977536.

135. Alves SS, Servilha-Menezes G, Rossi L, da Silva Junior RMP, Garcia-Cairasco N. Evidence of disturbed insulin signaling in animal models of Alzheimer's disease. Neuroscience & Biobehavioral Reviews. 2023;105326.

136. Chuvakova LN, Funikov SY, Rezvykh AP, Davletshin AI, Evgen'ev MB, Litvinova SA, et al. Transcriptome of the Krushinsky-Molodkina audiogenic rat strain and identification of possible audiogenic epilepsy-associated genes. Frontiers in Molecular Neuroscience. 2021;14:738930.

137. Sekar S, Marks WN, Gopalakrishnan V, Greba Q, Snutch TP, Howland JG, et al. Evidence for altered insulin signalling in the brains of genetic absence epilepsy rats from Strasbourg. Clin Exp Pharma Physio. 2020 Sep;47(9):1530–6.

138. Vöglein J, Ricard I, Noachtar S, Kukull WA, Dieterich M, Levin J, et al. Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. J Neurol. 2020 Oct;267(10):2941–8.

139. Nous A, Seynaeve L, Feys O, Wens V, De Tiège X, Van Mierlo P, et al. Subclinical epileptiform activity in the Alzheimer continuum: association with disease, cognition and detection method. Alz Res Therapy. 2024 Jan 23;16(1):19.

140. Zhang S, Lin S, Wang W, Gan Y, Wang C, Li B, et al. Developmental and epileptic encephalopathy 44 due to compound heterozygous variants in the UBA5 gene: a case report. Acta Epileptologica. 2023 Nov 13;5(1):27.

141. Arnadottir GA, Jensson BO, Marelsson SE, Sulem G, Oddsson A, Kristjansson RP, et al. Compound heterozygous mutations in UBA5 causing early-onset epileptic encephalopathy in two sisters. BMC Med Genet. 2017 Dec;18(1):103.

142. Mignon-Ravix C, Milh M, Kaiser CS, Daniel J, Riccardi F, Cacciagli P, et al. Abnormal function of the UBA5 protein in a case of early developmental and epileptic encephalopathy with suppression-burst. Human Mutation. 2018 Jul;39(7):934–8.

143. Miceli F, Soldovieri MV, Weckhuysen S, Cooper E, Taglialatela M. KCNQ2-related disorders. 2022 [cited 2024 Apr 16]; Available from: https://europepmc.org/article/nbk/nbk32534

144. Neubauer BA, Waldegger S, Heinzinger J, Hahn A, Kurlemann G, Fiedler B, et al. *KCNQ2* and *KCNQ3* mutations contribute to different idiopathic epilepsy syndromes. Neurology. 2008 Jul 15;71(3):177–83.

145. Kohlschütter A, Schulz A, Denecke J. Epilepsy in neuronal ceroid lipofuscinoses. Journal of Pediatric Epilepsy. 2014;3(4):199–206.

146. Asher YJT, Scaglia F. Molecular bases and clinical spectrum of early infantile epileptic encephalopathies. European journal of medical genetics. 2012;55(5):299–306.

147. Urak L, Feucht M, Fathi N, Hornik K, Fuchs K. A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity. Human molecular genetics. 2006;15(16):2533–41.

148. Gurba KN, Hernandez CC, Hu N, Macdonald RL. GABRB3 mutation, G32R, associated with childhood absence epilepsy alters α1β3γ2L γ-aminobutyric acid type A (GABAA) receptor expression and channel gating. Journal of Biological Chemistry. 2012;287(15):12083–97.

149. Papandreou A, McTague A, Trump N, Ambegaonkar G, Ngoh A, Meyer E, et al. *GABRB3* mutations: a new and emerging cause of early infantile epileptic encephalopathy. Develop Med Child Neuro. 2016 Apr;58(4):416–20.

150. Gardella E, Becker F, Møller RS, Schubert J, Lemke JR, Larsen LHG, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an *SCN8A* mutation. Annals of Neurology. 2016 Mar;79(3):428–36.

151. Fatema K, Rahman MM, Faruk O. SCN8A mutation in infantile epileptic encephalopathy: report of two cases. Journal of Epilepsy Research. 2019;9(2):147.

152. Saleh M, Helmi M, Yacop B. A Novel Nonsense Gene Variant Responsible for Early Infantile Epileptic Encephalopathy Type 39: Case Report. Pakistan Journal of Biological Sciences: PJBS. 2020;23(7):973–6.

153. Nashabat M, Al Qahtani XS, Almakdob S, Altwaijri W, Ba-Armah DM, Hundallah K, et al. The landscape of early infantile epileptic encephalopathy in a consanguineous population. Seizure. 2019;69:154–72.

154. Bender AC, Morse RP, Scott RC, Holmes GL, Lenck-Santini PP. SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome. Epilepsy & Behavior. 2012;23(3):177–86.

155. Miller IO, Sotero de Menezes MA. SCN1A seizure disorders. 2022 [cited 2024 Apr 18]; Available from: https://europepmc.org/article/nbk/nbk1318?client=bot&client=bot&client=bot&client=bot&client=bot

156. Myers KA, Scheffer IE. GRIN2A-related speech disorders and epilepsy. 2016 [cited 2024 Apr 18]; Available from: https://europepmc.org/article/nbk/nbk385627

157. Kingwell K. GRIN2A mutations identified as key genetic drivers of epilepsy–aphasia spectrum disorders. Nature Reviews Neurology. 2013;9(10):541–541.

158. Zweier M, Gregor A, Zweier C, Engels H, Sticht H, Wohlleber E, et al. Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression. Hum Mutat. 2010 Apr 6;31(6):722–33.

159. Verheyen S, Speicher MR, Ramler B, Plecko B. Childhood-onset epileptic encephalopathy due to *FGF12* exon 1–4 tandem duplication. Neurol Genet. 2020 Oct 5;6(5):e494.

160. Tian Q, Li H, Shu L, Wang H, Peng Y, Fang H, et al. Effective treatments for FGF12-related early-onset epileptic encephalopathies patients. Brain and Development. 2021;43(8):851–6.

161. Zhang L, Liu X. Clinical phenotype and genotype of children with GABAA receptor α1 subunit gene-related epilepsy. Frontiers in Neurology. 2022;13:941054.

162. Maljevic S, Krampfl K, Cobilanschi J, Tilgen N, Beyer S, Weber YG, et al. A mutation in the $GABA_A$ receptor α_1 subunit is associated with absence epilepsy. Annals of Neurology. 2006 Jun;59(6):983–7.

163. Cossette P, Liu L, Brisebois K, Dong H, Lortie A, Vanasse M, et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nature genetics. 2002;31(2):184–9.

164. Hernandez CC, Shen Y, Hu N, Shen W, Narayanan V, Ramsey K, et al. GABRG2 Variants associated with febrile seizures. Biomolecules. 2023;13(3):414.

Tables

Table 1. Demographic characteristics of AD and control cases.

Study	N	Tissue[a]	AD			Control		
			Female (%)	Age (mean,sd)	APOE ε4+ (%)	Female (%)	Age (mean,sd)	APOE ε4+ (%)
Knight ADRC	278	PC	60	83.8(8.6)	58.04	73.9	88.6(8.8)	0
MSBB	217	BM36	67.1	84.4(6.7)	19.29	66.6	80.6(8.3)	18.5
		BM10	67	84.2(6.8)	20.73	69.7	81.3(7.0)	15.1
		BM22	62.9	83.6(6.9)	23.38	70	81(8.0)	16.6
		BM44	66.6	84.3(6.7)	20.92	64.2	80.5(8.3)	17.8
ROSMAP	237	DLPFC	70.8	90.7(5.9)	39.58	53.7	84.1(6.8)	10.7

Table 2. Summary of the statistical information for the shared epilepsy genes

Gene	Knight ADRC		MSBB		ROSMAP		Directionality of change	Phenotype
	FC*	FDR	FC	FDR	FC	FDR		
CERS1	0.27	1.1e-03	0.67	3.7e-06	0.18	4.8e-02	Up	Progressive myoclonic epilepsies (PME) [39,41,42]
UBA5	-0.16	1.6e-04	-0.56	1.1e-12	-0.14	4.7e-02	Down	Early infantile epileptic encephalopathy (EIEE) [140–142]
KCNQ3	-0.23	4.8e-02	-0.38	5.5e-06	-0.35	3.0e-07	Down	Benign familial neonatal seizures (BFNS) [101,143,144]
PPT1	-0.24	4.9e-04	-0.41	3.5e-08	-0.11	3.7e-02	Down	Neuronal ceroid lipofuscinosis [109,111,145]
ARHGEF9	-0.25	9.4e-04	-0.34	1.5e-05	-0.18	4.2e-04	Down	EIEE [146]
GABRB3	-0.25	2.5e-02	-0.43	1.5e-06	-0.28	1.7e-05	Down	Childhood absence epilepsy (CAE) [147,148]/EIEE [149]
SCN8A	-0.25	4.1e-02	-0.3	2.6e-04	-0.23	8.6e-04	Down	Benign familial infantile seizures (BFIS) [150]/EIEE [151]
HCN1	-0.3	3.2e-02	-0.75	1.0e-10	-0.46	3.2e-07	Down	EIEE [65]
SLC25A12	-0.37	8.6e-06	-0.66	6.2e-11	-0.42	1.4e-09	Down	EIEE [152,153]
NECAP1	-0.4	4.3e-08	-0.83	1.0e-15	-0.34	1.4e-09	Down	EIEE [89]
SCN1A	-0.4	2.9e-03	-0.62	2.5e-05	-0.34	3.3e-05	Down	Dravet syndrome (DS)/Familial febrile seizures (FFS)/ Generalized epilepsy with febrile seizures plus (GEFS+) [154,155]
GRIN2A	-0.41	5.2e-04	-0.58	1.4e-08	-0.29	6.0e-05	Down	Focal epilepsy and speech disorder (FESD) [156,157]
MEF2C	-0.44	2.0e-04	-0.66	1.3e-09	-0.22	6.3e-04	Down	Mental retardation [158]
FGF12	-0.57	1.7e-06	-0.85	2.7e-14	-0.38	8.6e-07	Down	EIEE [159,160]
GABRA1	-0.68	2.5e-05	-0.93	1.2e-11	-0.23	1.5e-02	Down	EIEE/CAE/Juvenile myoclonic epilepsy (JME) [161–163]
GABRG2	-0.69	6.0e-06	-0.82	5.1e-11	-0.53	1.8e-08	Down	FFS/GEFS+/CAE [64,164]

* FC is the Fold Change in Log2 scale.

Figures Legends

Fig. 1: Dysregulated epilepsy-causing genes in the multi-omics profile associated with synaptic plasticity dysfunction (SPD) in AD. (**a**) Volcano plot showing the up-and downregulated genes identified between cases in the SPD profile vs other sporadic AD cases in the Knight ASRC cohort. (**b** and **c**) Same as "a" but in the MSBB and ROSMAP cohorts. (**c**) same as "a" and "b" but for ROSMAP cohort. (**d**) Venn diagrams depicting the number of dysregulated epilepsy-causing genes in each cohort as well as the overlap between them in three cohorts. (**e**) Heatmap of the expression profiles of the common epilepsy-causing genes from the knight ADRC cohort. (**f** and **g**) Same for "**e**" but from the MSBB and ROSMAP cohorts.

Fig. 2: Dysregulated epilepsy-causing genes in the SPD profile are highly expressed in neurons. (**a**) The RNA-seq expression of the dysregulated epilepsy-causing genes in human induced pluripotent stem cells (iPSC)-derived neurons**.** (**b**) The effect size of the overepxression of each of the dysregulated epilepsy-causing gene in a speicfic cell type relative to other cell types computed from single-nuclei data from the Knight ADRC participants. "N" indicates that no data was available for CERS1 in the single-nuclei data.

Fig. 3: Intersection between SPD profile in AD and epilepsy-related pathways. (**a**) Barplot showing the top 20 KEGG pathways. (**b**) Circle plot showing the epilepsy-causing genes invovled in each pathway. (c,d,e,f,g, and h) Same as "**a**" and "**b**" but for GO biological process, GO molecular function, and GO cellular component respectively.

Fig. 4: Epilepsy-causing gene are dysregulated at multiple stages of AD. (a) Venn diagrams showing the number of SPD dysregulated epilepsy-causing genes between early-AD vs control and late-AD vs control in the ROSMAP cohort, as well as the number of the common ones among the two comparisons. (b) Scatterplot showing the correlation of effect size between early-AD and late-AD for common SPD epilepsy-causing genes in the ROSMAP cohort.


a
Knight ADRC
−Log10 (PValue)
Log2 (Fold Change)
DOCK7
ST3GAL5
UBA5
NECAP1
FGF12
SLC25A12
GABRG2
ARV1
GABRA1
NHLRC1
Up
Down
No−change
b
MSBB
NECAP1
SCN2A
FGF12
UBA5
SZT2
GABRA1
CLCN2
PTEN
GABRG2
SLC25A12
c
ROSMAP
STXBP1
SLC12A5
SLC25A12
NECAP1
GABRG2
PRDM8
KCNQ3
EEF1A2
HCN1
FGF12
d
Knight ADRC (45)
MSBB (67)
ROSMAP (41)
8
17
25
16
4
9
12
e
Control
Other sAD
SPD
Knight ADRC
f
MSBB
g
ROSMAP
CERS1
NECAP1
FGF12
GABRG2
SLC25A12
GABRA1
UBA5
MEF2C
PPT1
GRIN2A
ARHGEF9
SCN1A
GABRB3
HCN1
SCN8A
KCNQ3


a
b
iPSC-Derived Neurons
Single-nuclei RNA-seq
UBA5
SLC25A12
SCN8A
SCN1A
PPT1
NECAP1
MEF2C
KCNQ3
HCN1
GRIN2A
GABRG2
GABRB3
GABRA1
FGF12
CERS1
ARHGEF9
N N N N N N
Neurons
Astrocytes
iMGL
Macrophages
Neuron
Astrocytes
Microglia
Oligo
Opc
Endo
RNA-seq Expression
0
2
4
6
8
Effect Size
−2
−1
0
1
2
3


a
KEGG Pathways
Nicotine addiction
Glutamatergic synapse
Amyotrophic lateral sclerosis
Dopaminergic synapse
Retrograde endocannabinoid signaling
Long−term potentiation
Neuroactive ligand−receptor interaction
GABAergic synapse
Morphine addiction
Circadian entrainment
Lysosome
Oxytocin signaling pathway
Cocaine addiction
Alzheimer disease
Amphetamine addiction
Rap1 signaling pathway
Taste transduction
Insulin secretion
Glucagon signaling pathway
Parathyroid hormone synthesis, secretion and action
0 2 4 6
−Log10(Pvalue)
b
GABRB3 GABRA1 GRIN2A GRIN2B GABRG2 SLC1A2 PLCB1 SCN1A SCARB2 CLN3 PPT1 MEF2C CACNB4 SCN2A SLC2A1
c
GO Biological Process
Regulation Of Postsynaptic Membrane Potential
Calcium Ion Transmembrane Import Into Cytosol
Regulation Of Synaptic Transmission, Glutamatergic
Chemical Synaptic Transmission
Glutamate Receptor Signaling Pathway
Regulation Of Monoatomic Cation Transmembrane Transport
Ionotropic Glutamate Receptor Signaling Pathway
Inhibitory Synapse Assembly
Synaptic Transmission, GABAergic
Nervous System Development
Anterograde Trans−Synaptic Signaling
Excitatory Postsynaptic Potential
Lysosomal Lumen Acidification
Gamma−Aminobutyric Acid Signaling Pathway
Regulation Of Lysosomal Lumen pH
Regulation Of Synapse Organization
Chemical Synaptic Transmission, Postsynaptic
Vacuolar Acidification
Sodium Ion Transport
Regulation Of Neuronal Synaptic Plasticity
0 2 4 6 8
−Log10(Pvalue)
d
GABRA1 GRIN2A MEF2C GRIN2B GABRG2 SCN8A SCN2A PLCB1 SCN1A CLN3 HCN1 GABRB3 CACNB4 SLC1A2 KCNQ3 FGF12 LGI1 ADGRV1 SLC2A1 PPT1 CLN6 CDKL5
e
GO Molecular Function
voltage−gated sodium channel activity
sulfatide binding
sodium channel activity
voltage−gated cation channel activity
GABA−gated chloride ion channel activity
ligand−gated anion channel activity
GABA−A receptor activity
GABA receptor activity
glutamate−gated calcium ion channel activity
transmitter−gated ion channel activity
NMDA glutamate receptor activity
benzodiazepine receptor activity
extracellular ligand−gated ion channel activity
chloride channel activity
inhibitory extracellular ligand−gated ion channel activity
L−glutamate transmembrane transporter activity
anion channel activity
acidic amino acid transmembrane transporter activity
C4−dicarboxylate transmembrane transporter activity
ionotropic glutamate receptor activity
0 2 4 6
−Log10(Pvalue)
f
SCN8A SCN2A HCN1 SCN1A CLN3 PPT1 CLN6 GRIN2A CACNB4 KCNQ3 GRIN2B GABRB3 GABRA1 GABRG2 SLC1A2 SLC25A12 SLC13A5
g
GO Cellular Component
Neuron Projection
Voltage−Gated Calcium Channel Complex
Calcium Channel Complex
Axon
NMDA Selective Glutamate Receptor Complex
Membrane Raft
GABA−A Receptor Complex
Sodium Channel Complex
Dendrite Membrane
Synaptic Membrane
Ionotropic Glutamate Receptor Complex
Postsynaptic Density Membrane
Dendrite
Postsynaptic Specialization Membrane
Asymmetric Synapse
Postsynaptic Density
Endoplasmic Reticulum Membrane
Late Endosome
Voltage−Gated Potassium Channel Complex
Lytic Vacuole
0 2 4 6
−Log10(Pvalue)
h
GABRB3 CLN3 GABRA1 SCN8A DOCK7 PPT1 SCN2A GRIN2B GABRG2 HCN1 CACNB4 SCN1A GRIN2A SLC1A2 CLN6 CDKL5 ARHGEF9 SCARB2 ARV1 UBA5 KCNQ3


a
Late-ADvsCO
(33)
Early−ADvsCO
(26)
8
25
1
b
$y = 0.0044 + 1.2\,x$
$p = 1.1e{-15}$
$R^2_{adj} = 0.94$
CERS1
WWOX
ST3GAL5
SCARB2
CACNB4
CDKL5
SCN1A
STRADA
SCN2A
SCN8A
KCNQ3
GABRB3
GUF1
PPT1
PRICKLE1
FGF12
UBA5
MEF2C
GABRA1
GRIN2A
HCN1
NHLRC1
ARHGEF9
NECAP1
GABRG2
Effect Size (Late−AD)
Effect Size (Early−AD)
0.2
0.0
−0.2
−0.4
−0.6
−0.4
−0.2
0.0
0.2